These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33738967)

  • 1. Logistic retainment interval dose exploration design for Phase I clinical trials of cytotoxic agents.
    Murray TA
    Pharm Stat; 2021 Jul; 20(4):850-863. PubMed ID: 33738967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bayesian approach to dose-finding studies for cancer therapies: incorporating later cycles of therapy.
    Sinclair K; Whitehead A
    Stat Med; 2014 Jul; 33(15):2665-80. PubMed ID: 24590816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.
    Shi H; Cao J; Yuan Y; Lin R
    Stat Med; 2021 May; 40(11):2626-2649. PubMed ID: 33650708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A simple Bayesian decision-theoretic design for dose-finding trials.
    Fan SK; Lu Y; Wang YG
    Stat Med; 2012 Dec; 31(28):3719-30. PubMed ID: 22763943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities.
    Zhou H; Chen C; Sun L; Zeng Z
    Contemp Clin Trials; 2021 Jun; 105():106404. PubMed ID: 33862287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
    Tighiouart M; Cook-Wiens G; Rogatko A
    J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information.
    Yang C; Li Y
    Stat Med; 2024 Feb; 43(4):689-705. PubMed ID: 38110304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probability-of-decision interval 3+3 (POD-i3+3) design for phase I dose finding trials with late-onset toxicity.
    Xu Z; Lin X
    Stat Methods Med Res; 2022 Mar; 31(3):534-548. PubMed ID: 34806915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
    Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
    Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
    Takahashi A; Suzuki T
    Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
    Gönen M
    Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian dose finding design for dual endpoint phase I trials.
    Loke YC; Tan SB; Cai Y; Machin D
    Stat Med; 2006 Jan; 25(1):3-22. PubMed ID: 16013039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.
    Cunanan K; Koopmeiners JS
    BMC Med Res Methodol; 2014 Apr; 14():51. PubMed ID: 24731155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials.
    Ishizuka N; Ohashi Y
    Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CFO: Calibration-free odds design for phase I/II clinical trials.
    Jin H; Yin G
    Stat Methods Med Res; 2022 Jun; 31(6):1051-1066. PubMed ID: 35238697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.
    Guo W; Wang SJ; Yang S; Lynn H; Ji Y
    Contemp Clin Trials; 2017 Jul; 58():23-33. PubMed ID: 28458054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.